CA3263118A1 - Formulation pharmaceutique orale stable contenant de l'hémifumarate de ruxolitinib - Google Patents
Formulation pharmaceutique orale stable contenant de l'hémifumarate de ruxolitinibInfo
- Publication number
- CA3263118A1 CA3263118A1 CA3263118A CA3263118A CA3263118A1 CA 3263118 A1 CA3263118 A1 CA 3263118A1 CA 3263118 A CA3263118 A CA 3263118A CA 3263118 A CA3263118 A CA 3263118A CA 3263118 A1 CA3263118 A1 CA 3263118A1
- Authority
- CA
- Canada
- Prior art keywords
- hemifumarate
- ruxolitinib
- pharmaceutical formulation
- formulation containing
- oral pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22382753 | 2022-08-03 | ||
| EP22382753.6 | 2022-08-03 | ||
| PCT/EP2023/070782 WO2024028193A1 (fr) | 2022-08-03 | 2023-07-26 | Formulation pharmaceutique orale stable contenant de l'hémifumarate de ruxolitinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3263118A1 true CA3263118A1 (fr) | 2024-02-08 |
Family
ID=82838976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3263118A Pending CA3263118A1 (fr) | 2022-08-03 | 2023-07-26 | Formulation pharmaceutique orale stable contenant de l'hémifumarate de ruxolitinib |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4565213A1 (fr) |
| AU (1) | AU2023318885A1 (fr) |
| CA (1) | CA3263118A1 (fr) |
| WO (1) | WO2024028193A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR2024005656A1 (tr) * | 2024-05-09 | 2025-11-21 | Abdi̇ İbrahi̇m İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Ruksolitin'in direkt baskı bir farmasötik tableti. |
| CN118986907B (zh) * | 2024-08-19 | 2025-07-08 | 青岛国信制药有限公司 | 一种磷酸芦可替尼片及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2455382B1 (fr) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Pyrrolo[2,3-b]pyridines et pyrrolo[2,3-b]pyrimidines à substitution hétéroaryle en tant qu'inhibiteurs de la janus kinase |
| EP3070090B1 (fr) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Utilisation des sels de l'inhibiteur de janus kinase (r)-3-(4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl) -3-cyclopentylpropanenitrile |
| US20150246043A1 (en) * | 2012-07-27 | 2015-09-03 | Ratiopharm Gmbh | Oral dosage forms for modified release comprising ruxolitinib |
| CN113384546A (zh) * | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
| WO2016026974A1 (fr) | 2014-08-21 | 2016-02-25 | Ratiopharm Gmbh | Sel d'oxalate de ruxolitinib |
| WO2016026975A1 (fr) | 2014-08-21 | 2016-02-25 | Ratiopharm Gmbh | Sel de (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile avec de l'acide benzènesulfonique |
| WO2016063294A2 (fr) | 2014-10-20 | 2016-04-28 | Msn Laboratories Private Limited | Procédé de préparation de phosphate de (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile et de ses polymorphes |
| CZ2014773A3 (cs) | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
| CZ2015496A3 (cs) | 2015-07-14 | 2017-01-25 | Zentiva, K.S. | Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava |
| CZ201629A3 (cs) | 2016-01-22 | 2017-08-02 | Zentiva, K.S. | Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy |
| CA3139457A1 (fr) | 2021-11-19 | 2023-05-19 | Apotex Inc. | Nouveaux sels de ruxolitinib et formes cristallines connexes |
-
2023
- 2023-07-26 EP EP23748998.4A patent/EP4565213A1/fr active Pending
- 2023-07-26 WO PCT/EP2023/070782 patent/WO2024028193A1/fr not_active Ceased
- 2023-07-26 AU AU2023318885A patent/AU2023318885A1/en active Pending
- 2023-07-26 CA CA3263118A patent/CA3263118A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4565213A1 (fr) | 2025-06-11 |
| AU2023318885A1 (en) | 2025-02-13 |
| WO2024028193A1 (fr) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3263118A1 (fr) | Formulation pharmaceutique orale stable contenant de l'hémifumarate de ruxolitinib | |
| EP4188329A4 (fr) | Formulations pharmaceutiques contenant du tadalafil | |
| EP4190310A4 (fr) | Préparation pharmaceutique stable | |
| EP4272734A4 (fr) | Formulation orale solide pour le nettoyage du côlon | |
| EP4230210A4 (fr) | Composition pharmaceutique stable | |
| EP4205765A4 (fr) | Préparation pharmaceutique stable | |
| IL320544A (en) | Oral pharmaceutical formulations containing 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENE-SULPHONAMIDE DERIVATIVES | |
| CA3262838A1 (fr) | Formulation pharmaceutique liquide orale stable d'un agent antispasmodique | |
| CA3261419A1 (fr) | Composition pharmaceutique comprenant de la centanafadine | |
| IL314206A (en) | Pharmaceutical formulation | |
| CA3305014A1 (fr) | Formulation pharmaceutique solide orale d'enzalutamide | |
| CA3289959A1 (fr) | Compositions pharmaceutiques orales | |
| HK40129184A (en) | Pharmaceutical formulation | |
| CA3266275A1 (fr) | Formulation pharmaceutique | |
| HK40113753A (en) | Pharmaceutical formulation | |
| CA3272561A1 (fr) | Formulations pharmaceutiques orales contenant des dérivés de 4-((2-hydroxy-3-méthoxybenzyl)amino)benzènesulfonamide | |
| CA3273940A1 (fr) | Compositions pharmaceutiques contenant de la doravirine et de l'islatravir | |
| AU2025906868A0 (en) | Sterile Stable Pharmaceutical Composition | |
| GB202417264D0 (en) | Pharmaceutical formulations | |
| GB202417258D0 (en) | Pharmaceutical formulations | |
| GB202417250D0 (en) | Pharmaceutical formulations | |
| CA3283561A1 (fr) | Forme posologique unitaire de film oral | |
| CA3296346A1 (fr) | Composition pharmaceutique contenant un lipide cationique et son utilisation | |
| CA3296099A1 (fr) | Formulation solide de pudafensine à administrer par voie orale | |
| CA3277361A1 (fr) | Formulations orales à libération contrôlée de médicaments lipophiles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20250123 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250425 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250425 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250425 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250425 |